Location: Solmed Polyclinic (Zagreb)
Study Drug: Experimental drug that blocks the formation of eosinophils that cause the disease.
Main Inclusion Criteria: Patients over 12 years of age with severe eosinophilic asthma, having experienced two exacerbation episodes in the last year requiring a doctor’s visit and intravenous corticosteroid administration. Additionally, patients must be taking inhaled corticosteroids and at least one other asthma medication, and they must not have smoked (or used electronic cigarettes) for at least 12 months before entering the trial.
Status: In preparation
Start of Patient Enrollment: June 2024
